In recent years, the prostate-specific membrane antigen (PSMA) has achieved a significant role in the diagnostics and treatments of patients with prostate cancer. Guidelines by the European Association of Urology (EAU) and the European Society of Medical Oncology (ESMO) recommend that patients who develop a recurrence after initial treatment with prostate-specific antigen (PSA) relapse undergo restaging PSMA PET/CT scans [1,2]. ESMO, the American Urology Association (AUA) and the Danish Prostate Cancer Study Group (DAPROCA) favor an early timescale for the restaging of PSMA PET/CT.
In 2021, the Federal Drugs Administration (FDA) approved restaging with a [68Ga]Ga-18 PSMA PET/CT at two United States (U.S.) institutions with a high expertise, following a randomized controlled trial [3]. In May 2021, the FDA also approved the routine use of [18F]FCG PyL PSMA PET/CT following two prospective single-arm studies, the CONDOR and the OSPREY trials [4,5]. Consensus documents on the acquisition of PSMA PET/CT, and a standardization of reporting on PSMA PET imaging, are emerging [6,7,8,9].
Although these guidelines and approvals indicate that the role of PSMA PET/CT is becoming increasingly established, access to PSMA PET/CT at a systemic level remains variable across jurisdictions, depending on regulatory environments [10].
The present issue of the International Journal of Molecular Sciences (IJMS) includes publications on staging using PSMA PET for the initial management of patients with prostate cancer [11] and on restaging using PSMA PET/CT for patients with prostate cancer at PSA relapse [12,13,14,15]. Other publications report the impact of the chemical structure of small inhibitory molecules for the PSMA receptor [16], animal models of PSMA and prostate cancer [17], and associations between the androgen receptor signal transduction pathway and the expression of PSMA [18,19,20].
Two randomized controlled trials, the TheraP and the VISION trial, proved the therapeutic efficacy of [177Lu]Lu-177 radioligand therapy (PRLT) as the third-line systemic treatment of patients with castration-resistant metastatic prostate cancer (mCRPC). A network meta-analysis of randomized trials of third-line systemic treatments of patients with mCRPC showed that PRLT gave the highest reported rate of 50% PSA decline after the treatments [21]. The FDA conducts an evaluation of PRLT as treatment of patients with mCRPC.
This Special Issue of IJMS also includes studies and reviews that report the adverse effects of PRLT [22] and clinical and nuclear medicine aspects that might contribute to optimizing the treatment of patients with mCRPC with PRLT [23].
Thus, this Special Issue of IJMS indicates the state of the art pointing to PSMA as a useful tool for the diagnosis and treatment of patients with prostate cancer. Specialists in nuclear medicine have an increasing role in multidisciplinary teams responsible for the treatment of patients with PSA relapse and mCRPC. In this Special Issue of the IJMS, the Editor and many authors collaborated to help physicians, patients, and others involved continue to better define the clinical impact and integration of PSMA theranostics across the disease spectrum of prostate cancer.
Author Contributions
Conceptualization: F.E.v.E.; original draft preparation: F.E.v.E. and G.B.; review and editing: F.E.v.E., G.B. and D.S.K.; supervision I.V. and G.P. All authors have read and agreed to the published version of the manuscript.
Funding
This editorial received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Cornford P., van den Bergh R.C.N., Briers E., van den Broeck T., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur. Urol. 2021;79:263–282. doi: 10.1016/j.eururo.2020.09.046. [DOI] [PubMed] [Google Scholar]
- 2.Parker C., Castro E., Fizazi K., Heidenreich A., Ost P., Procopio G., Tombal B., Gillessen S., on behalf of the ESMO Guidelines Committee Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31:1119–1134. doi: 10.1016/j.annonc.2020.06.011. [DOI] [PubMed] [Google Scholar]
- 3.Hofman M.S., Lawrentschuk N., Francis R.J., Tang C., Vela I., Thomas P., Rutherford N., Martin J.M., Frydenberg M., Shakher R., et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet. 2020;395:1208–1216. doi: 10.1016/S0140-6736(20)30314-7. [DOI] [PubMed] [Google Scholar]
- 4.Morris M.J., Rowe S.P., Gorin M.A., Saperstein L., Pouliot F., Josephson D., Wong J.Y.C., Pantel A.R., Cho S.Y., Gage K.L., et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR Phase III, multicenter study. Clin. Cancer Res. 2021;27:3674–3682. doi: 10.1158/1078-0432.CCR-20-4573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pienta K.J., Gorin M.A., Rowe S.P., Carroll P.R., Pouliot F., Probst S., Saperstein L., Preston M.A., Alva A.S., Patnaik A., et al. A Phase 2/3 prospective multicenter study of the diagnostic accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY) J. Urol. 2021;206:52–61. doi: 10.1097/JU.0000000000001698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Fanti S., Minozzi S., Morigi J.J., Giesel F., Ceci F., Uprimny C., Hofman M.S., Eiber M., Schwarzenbock S., Castellucci P., et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:1622–1635. doi: 10.1007/s00259-017-3725-1. [DOI] [PubMed] [Google Scholar]
- 7.Ceci F., Oprea-Lager D.E., Emmett L., Adam J.A., Bomanji J., Czernin J., Eiber M., Haberkorn U., Hofman M.S., Hope T.A., et al. E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:1626–1638. doi: 10.1007/s00259-021-05245-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J. Nucl. Med. 2018;59:469–478. doi: 10.2967/jnumed.117.198119. [DOI] [PubMed] [Google Scholar]
- 9.Werner R.A., Thackeray J.T., Pomper M.G., Bengel F.M., Gorin M.A., Derlin T., Rowe S.P. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J. Clin. Med. 2019;8:1060. doi: 10.3390/jcm8071060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shaygan B., Zukotynski K., Benard F., Menard C., Kuk J., Sistani G., Bauman G., Veit-Haibach P., Metser U. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Can. Urol. Assoc. J. 2021;15:162–172. doi: 10.5489/cuaj.7268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mapelli P., Ghezzo S., Gajate A.M.S., Preza E., Brembilla G., Cucchiara V., Ahmed N., Bezzi C., Presotto L., Bettinardi V., et al. Preliminary results of an ongoing prospective clinical trial on the use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in staging of high-risk prostate cancer patients. Diagnostics. 2021;11:2068. doi: 10.3390/diagnostics11112068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Von Eyben F.E., Soydal C., von Eyben R. 68Ga-PSMA PET/CT for patients with PSA relapse after radical prostatectomy or external beam radiotherapy. Diagnostics. 2021;11:622. doi: 10.3390/diagnostics11040622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jonmarker O., Axelsson R., Nilsson T., Gabrielson S. Comparison of regularized reconstruction and ordered subset expectation maximization reconstruction in the diagnostics of prostate cancer using digital time-of-flight 68Ga-PSMA-11 PET/CT imaging. Diagnostics. 2021;11:630. doi: 10.3390/diagnostics11040630. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Vlachostergios P.J., Zachos I., Tzortzis V. Biomarkers in prostate-specific membrane antigen theranostics. Diagnostics. 2021;11:1108. doi: 10.3390/diagnostics11061108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bayerschmidt S., Uprimny C., Kroiss A.S., Fritz J., Nilica B., Svirydenka H., Decristoforo C., von Guggenberg E., Horninger W., Virgolini I.J. Comparison of early imaging and imaging 60 min Post-Injection after forced diuresis with furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. Diagnostics. 2021;11:1191. doi: 10.3390/diagnostics11071191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Debnath S., Zhou N., Mclaughlin M., Rhee S., Pillai A., Hao G., Sun X. PSMA-Targetting imaging and theranostic agents—current status and future perspective. Int. J. Mol. Sci. 2022;23:1158. doi: 10.3390/ijms23031158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Stenberg V.Y., Larsen R.H., Ma L.W., Peng Q., Juzenas P., Bruland O.S., Juzeniene A. Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int. J. Mol. Sci. 2021;22:4815. doi: 10.3390/ijms22094815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Staniszewska M., Fragoso Costa P., Eiber M., Klose J.M., Wosniack J., Reis H., Szarvas T., Hadaschik B., Luckerath K., Herrmann K., et al. Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int. J. Mol. Sci. 2021;22:7431. doi: 10.3390/ijms22147431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kesler M., Druckmann I., Levine C., Kuten J., Yossepowitch O., Even-Sapir E. 68Ga-PSMA-11 PET/CT follow-up of patients with prostate cancer with bone metastases who had reduced bone density after androgen deprivation therapy. Diagnostics. 2021;11:277. doi: 10.3390/diagnostics11020277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Sommer H., Siciliano T., Ebersbach C., Beier A.-M.K., Stope M.B., Jahren K., Baretton G.B., Borkowetz A., Thomas C., Erb H.H.H. Impact of androgen receptor activity on prostate-specific membrane antigen expression in prostate cancer cells. Diagnostics. 2022;23:1046. doi: 10.3390/ijms23031046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Von Eyben F.E., Kairemo K., Paller C., Hoffmann M.A., Paganelli G., Virgolini I., Roviello G. 177Lu-PSMA radioligand therapy is favorable as third-Line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-Analysis of randomized controlled trials. Biomedicines. 2021;9:1042. doi: 10.3390/biomedicines9081042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Kesavan M., Meyrick D., Gallyamov M., Turner J.H., Yeo S., Cardaci G., Lenzo N.P. Efficacy and haematologic toxicity of palliative radioligand therapy of metastatic castrate-resistant prostate cancer with Lutetium-177-labeled prostate-specific membrane antigen in heavily pre-treated patients. Diagnostics. 2021;11:515. doi: 10.3390/diagnostics11030515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Von Eyben F.E., Bauman G., von Eyben R., Rahbar K., Soydal C., Haug A.R., Virgolini I., Kulkarni H., Baum R., Paganelli G. Optimizing PSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis. Int. J. Mol. Sci. 2020;21:9054. doi: 10.3390/ijms21239054. [DOI] [PMC free article] [PubMed] [Google Scholar]